Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis

Taxiarchis Kourelis, M. N. Moustakakis, R. Silk, D. Pharm, A. Boruchov, S. F. Bilgrami

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Treatment of patients with Acute Myeloid Leukemia (AML) undergoing hemodialysis is especially challenging since there are no specific management guidelines for the administration of cytotoxic agents in these patients. Well established chemotherapy protocols may be unsuitable in such cases because of altered drug pharmacokinetics, increased risk for complications, and underlying co-morbidities. In addition, these patients are at an increased risk for complications such as tumor lysis syndrome. Herein, we report the first use of decitabine in a patient on hemodialysis. He presented with a new diagnosis of AML and achieved hematologic remission following the use of induction chemotherapy and maintenance decitabine.

Original languageEnglish (US)
Pages (from-to)289-292
Number of pages4
JournalEuropean Journal of Inflammation
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

decitabine
Acute Myeloid Leukemia
Renal Dialysis
Tumor Lysis Syndrome
Induction Chemotherapy
Cytotoxins
Pharmacokinetics
Maintenance
Guidelines
Morbidity
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Acute myeloid leukemia
  • Decitabine
  • Hemodialysis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis. / Kourelis, Taxiarchis; Moustakakis, M. N.; Silk, R.; Pharm, D.; Boruchov, A.; Bilgrami, S. F.

In: European Journal of Inflammation, Vol. 9, No. 3, 01.01.2011, p. 289-292.

Research output: Contribution to journalArticle

Kourelis, Taxiarchis ; Moustakakis, M. N. ; Silk, R. ; Pharm, D. ; Boruchov, A. ; Bilgrami, S. F. / Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis. In: European Journal of Inflammation. 2011 ; Vol. 9, No. 3. pp. 289-292.
@article{fc45129a29224f2694a9454b12d425ce,
title = "Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis",
abstract = "Treatment of patients with Acute Myeloid Leukemia (AML) undergoing hemodialysis is especially challenging since there are no specific management guidelines for the administration of cytotoxic agents in these patients. Well established chemotherapy protocols may be unsuitable in such cases because of altered drug pharmacokinetics, increased risk for complications, and underlying co-morbidities. In addition, these patients are at an increased risk for complications such as tumor lysis syndrome. Herein, we report the first use of decitabine in a patient on hemodialysis. He presented with a new diagnosis of AML and achieved hematologic remission following the use of induction chemotherapy and maintenance decitabine.",
keywords = "Acute myeloid leukemia, Decitabine, Hemodialysis",
author = "Taxiarchis Kourelis and Moustakakis, {M. N.} and R. Silk and D. Pharm and A. Boruchov and Bilgrami, {S. F.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1177/1721727X1100900310",
language = "English (US)",
volume = "9",
pages = "289--292",
journal = "European Journal of Inflammation",
issn = "1721-727X",
publisher = "Biolife",
number = "3",

}

TY - JOUR

T1 - Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis

AU - Kourelis, Taxiarchis

AU - Moustakakis, M. N.

AU - Silk, R.

AU - Pharm, D.

AU - Boruchov, A.

AU - Bilgrami, S. F.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Treatment of patients with Acute Myeloid Leukemia (AML) undergoing hemodialysis is especially challenging since there are no specific management guidelines for the administration of cytotoxic agents in these patients. Well established chemotherapy protocols may be unsuitable in such cases because of altered drug pharmacokinetics, increased risk for complications, and underlying co-morbidities. In addition, these patients are at an increased risk for complications such as tumor lysis syndrome. Herein, we report the first use of decitabine in a patient on hemodialysis. He presented with a new diagnosis of AML and achieved hematologic remission following the use of induction chemotherapy and maintenance decitabine.

AB - Treatment of patients with Acute Myeloid Leukemia (AML) undergoing hemodialysis is especially challenging since there are no specific management guidelines for the administration of cytotoxic agents in these patients. Well established chemotherapy protocols may be unsuitable in such cases because of altered drug pharmacokinetics, increased risk for complications, and underlying co-morbidities. In addition, these patients are at an increased risk for complications such as tumor lysis syndrome. Herein, we report the first use of decitabine in a patient on hemodialysis. He presented with a new diagnosis of AML and achieved hematologic remission following the use of induction chemotherapy and maintenance decitabine.

KW - Acute myeloid leukemia

KW - Decitabine

KW - Hemodialysis

UR - http://www.scopus.com/inward/record.url?scp=84858629916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858629916&partnerID=8YFLogxK

U2 - 10.1177/1721727X1100900310

DO - 10.1177/1721727X1100900310

M3 - Article

AN - SCOPUS:84858629916

VL - 9

SP - 289

EP - 292

JO - European Journal of Inflammation

JF - European Journal of Inflammation

SN - 1721-727X

IS - 3

ER -